The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Deferasirox Mylan deferasirox Generic | Mylan Pharmaceuticals Limited | Iron Overload; beta-Thalassemia | 🇪🇺 EU 2019-09-26 | Order → |
| Trogarzo ibalizumab Additional monitoring | Theratechnologies Europe Limited | HIV Infections | 🇪🇺 EU 2019-09-26 | Order → |
| Epidyolex cannabidiol Orphan | Jazz Pharmaceuticals Ireland Limited | Lennox Gastaut Syndrome; Epilepsies, Myoclonic | 🇪🇺 EU 2019-09-19 | Order → |
| Inbrija levodopa | Merz Therapeutics GmbH | Parkinson Disease | 🇪🇺 EU 2019-09-19 | Order → |
| Vitrakvi larotrectinib ConditionalAdditional monitoring | Bayer AG | Abdominal Neoplasms | 🇪🇺 EU 2019-09-19 | Order → |
| Lacosamide UCB lacosamide | UCB Pharma S.A. | Epilepsies, Partial | 🇪🇺 EU 2019-08-26 | Order → |
| Giapreza angiotensin II Additional monitoring | Paion Pharma GmbH | Hypotension; Shock | 🇪🇺 EU 2019-08-23 | Order → |
| Azacitidine Celgene azacitidine | Celgene Europe BV | Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute | 🇪🇺 EU 2019-08-02 | Order → |
| Cufence trientine dihydrochloride | Univar Solutions BV | Hepatolenticular Degeneration | 🇪🇺 EU 2019-07-25 | Order → |
| LysaKare arginine;lysine | Novartis Europharm Limited | Radiation Injuries | 🇪🇺 EU 2019-07-25 | Order → |
| Posaconazole Accord posaconazole Generic | Accord Healthcare S.L.U. | Mycoses | 🇪🇺 EU 2019-07-25 | Order → |
| Posaconazole AHCL posaconazole Generic | Accord Healthcare S.L.U. | Mycoses | 🇪🇺 EU 2019-07-25 | Order → |
| Ultomiris ravulizumab | Alexion Europe SAS | Hemoglobinuria, Paroxysmal | 🇪🇺 EU 2019-07-02 | Order → |
| Dovato dolutegravir;lamivudine | ViiV Healthcare B.V. | HIV Infections | 🇪🇺 EU 2019-07-01 | Order → |
| Xromi hydroxycarbamide | Lipomed GmbH | Anemia, Sickle Cell | 🇪🇺 EU 2019-07-01 | Order → |
| Libtayo cemiplimab | Regeneron Ireland Designated Activity Company (DAC) | Carcinoma, Squamous Cell | 🇪🇺 EU 2019-06-28 | Order → |
| Striascan ioflupane (123l) Generic | CIS bio international | Radionuclide Imaging; Dementia; Movement Disorders | 🇪🇺 EU 2019-06-25 | Order → |
| Ambrisentan Viatris (previously Ambrisentan Mylan) ambrisentan Generic | Viatris Limited | Hypertension, Pulmonary | 🇪🇺 EU 2019-06-20 | Order → |
| Doptelet avatrombopag | Swedish Orphan Biovitrum AB (publ) | Thrombocytopenia | 🇪🇺 EU 2019-06-20 | Order → |
| Esperoct turoctocog alfa pegol Additional monitoring | Novo Nordisk A/S | Hemophilia A | 🇪🇺 EU 2019-06-20 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.